News releases from Promise, and who to contact if you are reporting on prescription peptide care, compounding rules or telehealth licensure. Each release links to the longer analysis we published alongside it.
Press
Press and media
Last updated: September 17, 2026
In brief.
News releases
FDA Advisory Panel Backs BPC-157 for 503A Bulks List in 8-6-1 Vote, Promise Analysis Finds
September 8, 2026 · PR Newswire · carried by Yahoo Finance. Our analysis: Why BPC-157 is still not FDA-approved
Promise Launches Clinician-Guided BPC-157 Evaluation as FDA Panel Backs 503A Bulks List Addition
September 8, 2026 · FinanceWire · carried by Markets Insider. Our analysis: The 503A bulks list, explained
Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month
August 21, 2026 · FinanceWire · carried by Markets Insider. Our analysis: The Interstate Medical Licensure Compact
Your Telehealth Doctor Must Be Licensed in the State You're In, Not the State They're In, Promise Analysis Finds
August 20, 2026 · PR Newswire · carried by Yahoo Finance. Our analysis: Telehealth doctors and state licensure
Media contact
Stacey · stacey@mypromise.com · (480) 999-3519 · Scottsdale, Arizona
About Promise
Promise is a telehealth platform founded in 2026 and based in Scottsdale, Arizona. It connects patients with licensed providers for peptide therapy, weight management and hormone care. Every treatment request is reviewed by a licensed provider, who prescribes only when treatment is appropriate, and prescriptions are filled by licensed U.S. compounding pharmacies. Compounded medications are not FDA-approved.
Promise is operated by myPromise, LLC, 7135 E Camelback Rd, Suite 230, Scottsdale, AZ 85251.
Quoting our research
You are welcome to quote Promise articles with a link back to the piece. Every article lists its primary sources, and our editorial standards explain how we check them.